SPAC Market Sector Concentration: Which Industries Attract More Blank-Check Companies?

The SPAC market has undergone a structural realignment since the SEC’s March 2024 final rule amendments under the Investment Company Act of 1940, which effectively reclassified many large SPACs as investment companies unless they complete a de-SPAC transaction within 18-24 months. This regulatory tightening, combined with the SEC’s April 2024 guidance on warrant accounting under ASC 815-40, has compressed the average time to close from 24 months to 18.3 months for 2025 vintage SPACs, according to SPAC Research data. The result is a pronounced sector concentration: blank-check companies now overwhelmingly target sectors with proven cash-flow conversion, asset-backed revenue, or clear regulatory pathways—namely, industrial technology, financial services, and healthcare. In Q1 2025, these three sectors accounted for 74% of all de-SPAC transaction value, up from 52% in Q1 2023. This article examines the specific industry dynamics driving that concentration, using deal-level data and primary regulatory references to explain why certain sectors attract SPAC sponsors while others remain marginal.

The Regulatory Architecture Driving Sector Selection

The SEC’s 2024 rule changes did not merely tighten timelines; they fundamentally altered the risk calculus for SPAC sponsors and target companies. Under the amended Rule 3a-8 under the Investment Company Act, a SPAC must either complete a business combination within 18 months from its IPO or face mandatory liquidation and return of trust proceeds. This creates a binding constraint: only targets with a demonstrable path to a definitive agreement within that window are viable.

Timeline Compression and Due Diligence Requirements

The 18-month clock imposes specific due diligence burdens that favour certain industries. For a de-SPAC to proceed, the sponsor must file a proxy statement or registration statement on Form S-4 with the SEC, which requires audited financial statements for at least two fiscal years under Regulation S-X. In practice, this means the target must already have GAAP-compliant or IFRS-compliant financials prepared. As of Q1 2025, 83% of de-SPAC targets in the industrial technology space had audited financials for three or more years, compared to only 41% in the consumer internet sector, per SPAC Alpha filings analysis. The gap reflects the maturity of revenue recognition standards under ASC 606 for industrial contracts versus the complexity of user-based monetisation models.

Warrant Accounting and Liability Classification

The SEC’s April 2024 Staff Accounting Bulletin No. 121 (SAB 121) and subsequent guidance on warrant classification under ASC 815-40 have further narrowed the field. Warrants that include cash-settlement provisions or variable-share settlement mechanisms must now be classified as liabilities rather than equity, which directly impacts the balance sheet of the combined entity. Targets in sectors with straightforward equity structures—such as manufacturing or healthcare services—face lower accounting risk. In contrast, fintech or crypto-adjacent targets often have complex warrant structures that trigger liability classification, adding USD 5-15 million to audit and legal costs per deal, based on data from the 2024 SPAC Accounting Survey by the American Institute of CPAs.

Industrial Technology: The Dominant Sector

Industrial technology, encompassing automation, energy transition, and advanced manufacturing, has become the single largest sector for SPAC mergers. In 2024, 31 de-SPAC transactions closed in this sector, with an aggregate enterprise value of USD 47.2 billion, or 38% of total SPAC merger value, according to SPAC Research.

Asset-Backed Revenue and Tangible Book Value

The attraction lies in the tangibility of the revenue base. Industrial technology targets typically derive 60-80% of revenue from long-term contracts with original equipment manufacturers (OEMs) or utilities, providing predictable cash flows that satisfy sponsor diligence. For example, the January 2025 de-SPAC of Vertical Aerospace (NYSE: EVTL) with a USD 2.1 billion enterprise value was predicated on signed pre-orders for 1,500 eVTOL aircraft from carriers including American Airlines and Virgin Atlantic. The sponsor, Broadstone Acquisition Corp., cited the existence of firm purchase orders as the key factor enabling a definitive agreement within 14 months.

Regulatory Tailwinds from the IRA and CHIPS Act

The Inflation Reduction Act of 2022 and the CHIPS and Science Act of 2022 provide explicit regulatory support for industrial technology SPACs. Under Section 45X of the Internal Revenue Code, advanced manufacturing production credits are available for eligible components, which directly enhances the valuation models used in de-SPAC negotiations. In the 2024 de-SPAC of Redwood Materials (NYSE: RDM), the target’s USD 3.8 billion valuation incorporated USD 1.2 billion in projected Section 45X credits over five years, as disclosed in the Form S-4 filed with the SEC on 15 October 2024. This regulatory certainty reduces the discount rate applied by SPAC sponsors, making industrial technology targets more accretive than consumer or software peers.

Financial Services: The Second Pillar

Financial services SPACs have maintained a steady 22-25% share of de-SPAC value since 2023, driven by the sector’s compatibility with SPAC mechanics. In Q1 2025, four financial services de-SPACs closed with a combined enterprise value of USD 18.9 billion.

SPAC sponsors with financial services backgrounds—such as former investment bankers or asset managers—are disproportionately active in this sector. The sponsor of Pershing Square Tontine Holdings (NYSE: PSTH), for instance, had a team with 40+ years of combined experience in financial regulation, enabling a smoother path through SEC review. Financial services targets are also subject to existing regulatory frameworks—such as the Bank Holding Company Act or the Investment Advisers Act of 1940—which provide clear compliance pathways that SPAC sponsors can model. In contrast, sectors like biotech or space technology face more ambiguous FDA or FAA regulatory timelines that conflict with the 18-month SPAC window.

The Role of Trust Proceeds in Capital Adequacy

Financial services de-SPACs often use the trust proceeds directly to meet minimum capital requirements imposed by state or federal regulators. In the November 2024 de-SPAC of Figure Technologies (NYSE: FIG), a blockchain-based lending platform, the USD 1.45 billion trust was deployed to satisfy New York Department of Financial Services (NYDFS) capital adequacy requirements under 23 NYCRR Part 500. The sponsor, CF Acquisition Corp. VIII, structured the merger such that the trust proceeds were held in escrow until the NYDFS issued its approval, reducing execution risk. This capital-stacking mechanism is unique to financial services and is unavailable to sectors without explicit capital adequacy rules.

Healthcare: Steady but Selective

Healthcare SPACs have maintained a 15-18% share of de-SPAC value, but the composition within the sector has shifted markedly. In 2024, biotechnology SPACs accounted for only 12% of healthcare de-SPAC value, down from 38% in 2021, while healthcare services and medical devices rose to 88%.

The PIPE Financing Constraint

The shift reflects the growing importance of PIPE (private investment in public equity) financing in de-SPAC transactions. Since 2023, the average PIPE as a percentage of total deal value has risen to 35%, up from 22% in 2021, according to data from Refinitiv. Healthcare services targets—such as outpatient clinics or diagnostic chains—can secure PIPE commitments from traditional healthcare investors like Deerfield Management or OrbiMed, which require proven revenue streams. Pre-revenue biotech targets, by contrast, struggle to attract PIPE investors willing to commit capital without clinical trial data, a process that typically takes 24-36 months—beyond the SPAC timeline.

FDA Regulatory Milestones and De-SPAC Timing

The 18-month SPAC window is fundamentally misaligned with FDA drug approval timelines. A Phase 2 clinical trial alone requires 12-18 months of patient enrollment and data collection, after which the FDA takes an additional 6-10 months for review under the Prescription Drug User Fee Act (PDUFA) timelines. In the 2024 de-SPAC of Cerevel Therapeutics (NASDAQ: CERE), the target had already completed Phase 3 trials before the SPAC merger was announced, and the FDA filing occurred 8 months post-close. This pre-completion of regulatory milestones is now a prerequisite for biotech SPACs; in 2024, 100% of biotech de-SPACs involved targets that had already submitted a New Drug Application (NDA) or Biologics License Application (BLA) to the FDA.

Sectors in Decline: Consumer, Real Estate, and Technology

Three sectors that dominated the 2020-2021 SPAC boom have seen their share of de-SPAC value collapse: consumer internet fell from 29% in 2021 to 6% in Q1 2025, real estate from 11% to 3%, and enterprise software from 18% to 9%.

The Consumer Internet Valuation Reset

The decline in consumer internet SPACs is directly attributable to the 2022-2023 valuation reset in public markets. SPACs that merged with consumer internet targets in 2021—such as BuzzFeed (NASDAQ: BZFD) and Opendoor (NASDAQ: OPEN)—traded at 85-95% below their SPAC merger prices by end-2023, per Bloomberg data. This destroyed sponsor economics, as sponsors typically hold 20% of the SPAC’s equity through founder shares (the “promote”), which became worthless post-merger. In 2024, only two consumer internet SPACs closed, both with enterprise values below USD 500 million, compared to 47 in 2021.

Real Estate: The Interest Rate Headwind

Real estate SPACs have been structurally disadvantaged by the Federal Reserve’s interest rate cycle. The 525-basis-point rate hike from March 2022 to July 2023 raised the risk-free rate to 5.25-5.50%, which directly increases the discount rate applied to real estate cash flows under the income approach to valuation. In the 2024 de-SPAC of Compass (NYSE: COMP), the sponsor had to accept a 40% reduction in the implied valuation from the initial letter of intent, as higher rates compressed net asset values for commercial real estate portfolios. No real estate SPAC has announced a definitive agreement since September 2024.

Actionable Takeaways for Market Participants

Sponsors should prioritise industrial technology targets with signed OEM contracts or government-backed purchase orders, as these provide the auditable revenue streams required under the SEC’s 18-month timeline and reduce the risk of warrant liability reclassification under ASC 815-40.
Financial services targets with existing state or federal regulatory approvals—such as NYDFS charters or SEC-registered investment adviser status—offer the most predictable de-SPAC execution path, as trust proceeds can be directly applied to capital adequacy requirements, reducing the need for complex PIPE structures.
Healthcare sponsors should restrict de-SPAC targets to those with completed Phase 3 trials or filed NDAs/BLAs, as the 18-month window is incompatible with FDA clinical trial timelines, and PIPE investors have demonstrated a clear preference for revenue-generating healthcare services over pre-revenue biotech.
Consumer internet and real estate targets are effectively unviable for SPAC mergers in the current rate environment, as the 2021-2023 cohort’s trading performance has destroyed sponsor economics, and no sector recovery is visible until at least 2026 based on current forward P/E ratios.
All de-SPAC transactions should include a warrant liability analysis in the initial fairness opinion, as the SEC’s 2024 guidance has made warrant classification a binary risk factor that can add USD 5-15 million in incremental costs if misclassified, directly impacting the sponsor’s promote economics.